Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SGEN's Cash to Debt is ranked higher than
82% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. SGEN: No Debt )
SGEN' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.46
SGEN's Equity to Asset is ranked higher than
62% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SGEN: 0.46 )
SGEN' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.97
Current: 0.46

0.36
0.97
Interest Coverage No Debt
SGEN's Interest Coverage is ranked higher than
72% of the 576 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SGEN: No Debt )
SGEN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 9.25
M-Score: -2.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -26.98
SGEN's Operating margin (%) is ranked higher than
78% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. SGEN: -26.98 )
SGEN' s 10-Year Operating margin (%) Range
Min: -9958.59   Max: -23.35
Current: -26.98

-9958.59
-23.35
Net-margin (%) -26.55
SGEN's Net-margin (%) is ranked higher than
78% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. SGEN: -26.55 )
SGEN' s 10-Year Net-margin (%) Range
Min: -7917.17   Max: -23.22
Current: -26.55

-7917.17
-23.22
ROE (%) -33.90
SGEN's ROE (%) is ranked higher than
74% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. SGEN: -33.90 )
SGEN' s 10-Year ROE (%) Range
Min: -128.57   Max: -24.17
Current: -33.9

-128.57
-24.17
ROA (%) -16.09
SGEN's ROA (%) is ranked higher than
78% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. SGEN: -16.09 )
SGEN' s 10-Year ROA (%) Range
Min: -50.86   Max: -12
Current: -16.09

-50.86
-12
ROC (Joel Greenblatt) (%) -181.45
SGEN's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. SGEN: -181.45 )
SGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -903.49   Max: -178.02
Current: -181.45

-903.49
-178.02
Revenue Growth (3Y)(%) 40.30
SGEN's Revenue Growth (3Y)(%) is ranked higher than
92% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. SGEN: 40.30 )
SGEN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 7.3   Max: 157.1
Current: 40.3

7.3
157.1
EBITDA Growth (3Y)(%) -24.70
SGEN's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. SGEN: -24.70 )
SGEN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -30.2   Max: 18
Current: -24.7

-30.2
18
EPS Growth (3Y)(%) -22.70
SGEN's EPS Growth (3Y)(%) is ranked higher than
76% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. SGEN: -22.70 )
SGEN' s 10-Year EPS Growth (3Y)(%) Range
Min: -34   Max: 27.9
Current: -22.7

-34
27.9
» SGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SGEN Guru Trades in Q1 2014

Ray Dalio 22,400 sh (New)
Jim Simons 268,713 sh (+113.24%)
PRIMECAP Management 11,007,005 sh (+0.49%)
Columbia Wanger 6,626,000 sh (-1.12%)
Manning & Napier Advisors, Inc 272,980 sh (-26.06%)
Steven Cohen 16,034 sh (-43.45%)
» More
Q2 2014

SGEN Guru Trades in Q2 2014

Manning & Napier Advisors, Inc 399,490 sh (+46.34%)
Jim Simons Sold Out
Ray Dalio Sold Out
Columbia Wanger 6,610,000 sh (-0.24%)
PRIMECAP Management 10,895,800 sh (-1.01%)
» More
Q3 2014

SGEN Guru Trades in Q3 2014

Ray Dalio 6,140 sh (New)
Manning & Napier Advisors, Inc 485,810 sh (+21.61%)
PRIMECAP Management 10,954,900 sh (+0.54%)
Columbia Wanger 5,155,000 sh (-22.01%)
» More
Q4 2014

SGEN Guru Trades in Q4 2014

PRIMECAP Management 11,178,050 sh (+2.04%)
Manning & Napier Advisors, Inc 485,810 sh (unchged)
Ray Dalio Sold Out
Columbia Wanger 4,474,100 sh (-13.21%)
» More
» Details

Insider Trades

Latest Guru Trades with SGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ray Dalio 2014-12-31 Sold Out $31.1 - $37.8 $ 35.121%0
Ray Dalio 2014-09-30 New Buy$33.75 - $44.14 $ 35.12-11%6140
Ray Dalio 2014-06-30 Sold Out 0.01%$32.82 - $46.79 $ 35.12-7%0
Ray Dalio 2014-03-31 New Buy0.01%$38.57 - $55.14 $ 35.12-26%22400
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 20.60
SGEN's P/B is ranked higher than
59% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. SGEN: 20.60 )
SGEN' s 10-Year P/B Range
Min: 1.64   Max: 29.21
Current: 20.6

1.64
29.21
P/S 15.20
SGEN's P/S is ranked higher than
79% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. SGEN: 15.20 )
SGEN' s 10-Year P/S Range
Min: 9.98   Max: 50.53
Current: 15.2

9.98
50.53
EV-to-EBIT -44.14
SGEN's EV-to-EBIT is ranked higher than
53% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SGEN: -44.14 )
SGEN' s 10-Year EV-to-EBIT Range
Min: -102.6   Max: -2.8
Current: -44.14

-102.6
-2.8
Current Ratio 3.24
SGEN's Current Ratio is ranked higher than
75% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. SGEN: 3.24 )
SGEN' s 10-Year Current Ratio Range
Min: 2.75   Max: 31.28
Current: 3.24

2.75
31.28
Quick Ratio 2.90
SGEN's Quick Ratio is ranked higher than
73% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. SGEN: 2.90 )
SGEN' s 10-Year Quick Ratio Range
Min: 2.75   Max: 31.28
Current: 2.9

2.75
31.28
Days Inventory 421.05
SGEN's Days Inventory is ranked higher than
79% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SGEN: 421.05 )
SGEN' s 10-Year Days Inventory Range
Min: 442.93   Max: 639.76
Current: 421.05

442.93
639.76
Days Sales Outstanding 49.96
SGEN's Days Sales Outstanding is ranked higher than
84% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. SGEN: 49.96 )
SGEN' s 10-Year Days Sales Outstanding Range
Min: 25.55   Max: 1028.64
Current: 49.96

25.55
1028.64

Valuation & Return

vs
industry
vs
history
Price/Net Cash 66.30
SGEN's Price/Net Cash is ranked higher than
75% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. SGEN: 66.30 )
SGEN' s 10-Year Price/Net Cash Range
Min: 3.73   Max: 60.62
Current: 66.3

3.73
60.62
Price/Net Current Asset Value 37.40
SGEN's Price/Net Current Asset Value is ranked higher than
75% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. SGEN: 37.40 )
SGEN' s 10-Year Price/Net Current Asset Value Range
Min: 3.68   Max: 35.63
Current: 37.4

3.68
35.63
Price/Tangible Book 20.90
SGEN's Price/Tangible Book is ranked higher than
64% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. SGEN: 20.90 )
SGEN' s 10-Year Price/Tangible Book Range
Min: 1.78   Max: 24.23
Current: 20.9

1.78
24.23
Price/Median PS Value 0.70
SGEN's Price/Median PS Value is ranked higher than
93% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. SGEN: 0.70 )
SGEN' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 27.14
Current: 0.7

0.6
27.14
Earnings Yield (Greenblatt) -2.30
SGEN's Earnings Yield (Greenblatt) is ranked higher than
83% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. SGEN: -2.30 )
SGEN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.3   Max: 0
Current: -2.3

-2.3
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SGT.Germany,
Seattle Genetics Inc was incorporated on July 15, 1997. It is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. In August 2011, the U.S. Food and Drug Administration, or FDA, granted accelerated approval of ADCETRIS, or brentuximab vedotin, in two indications; the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant, or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and the treatment of patients with systemic anaplastic large cell lymphoma, or sALCL, after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing the Companys proprietary technology. The Company collaborated with Takeda Pharmaceutical Company Limited, or Takeda, to develop and commercialize ADCETRIS. The Company has a broad development strategy for ADCETRIS evaluating its potential application in earlier lines of therapy in patients with Hodgkin lymphoma and sALCL and other CD30-positive malignancies. In addition, it has five clinical-stage ADC programs, which consist of SGN-CD19A, SGN-CD33A, SGN-LIV1A, ASG-22ME, and ASG-15ME. Many third parties compete with the Company in developing various approaches to cancer and autoimmune disease therapy. They include pharmaceutical companies, biotechnology companies, academic institutions and other research organizations. The Company operates under the regulations of FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries.
» More Articles for NAS:SGEN

Headlines

Articles On GuruFocus.com
Seattle Genetics: Can Record Growth From Its Licenses Oct 28 2014 
Seattle Genetics: Can Record Sustained Growth From Royalty Aug 31 2014 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
Comment for Companies Ranked by Business Predictability Jan 03 2013 
Weekly CFO Sells Highlight: SGEN, PFIE, MAR, ESRX, LIOX, RGEN Sep 10 2012 
WEEKLY CFO SELLS HIGHLIGHT: SBAC, XOXO, MTH, FICO, SGEN, OAS Sep 03 2012 
Weekly CFO Sells Highlight: SWKS, P, SGEN, RT Jun 11 2012 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Weekly CFO Sells Highlight: SGEN, APKT, AMRC, FNGN Oct 10 2011 

More From Other Websites
American Express, General Electric And Other Stocks Insiders Have Been Buying Mar 01 2015
Seattle Genetics to Present at Upcoming Investor Conferences Feb 26 2015
Seattle Genetics to Present at Upcoming Investor Conferences Feb 25 2015
Seattle Genetics (SGEN) Filed Supplemental BLA for Adcetris - Analyst Blog Feb 19 2015
Seattle Genetics' SEA-CD40 Enters Phase I for Solid Tumors - Analyst Blog Feb 18 2015
Seattle Genetics Submits Supplemental BLA to FDA for Phase 3 AETHERA Trial of ADCETRIS®... Feb 18 2015
Seattle Genetics Submits Supplemental BLA to FDA for Phase 3 AETHERA Trial of ADCETRIS®... Feb 18 2015
Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced... Feb 17 2015
Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced... Feb 17 2015
Ceiling seen for Seattle Genetics Feb 12 2015
Seattle Genetics Posts Narrower-than-Expected Loss in Q4 - Analyst Blog Feb 11 2015
Seattle Genetics reports 4Q loss Feb 10 2015
Seattle Genetics reports 4Q loss Feb 10 2015
Seattle Genetics Inc Earnings Call scheduled for 4:30 pm ET today Feb 10 2015
SEATTLE GENETICS INC /WA Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 10 2015
Seattle Genetics Reports Fourth Quarter and Year 2014 Financial Results Feb 10 2015
Q4 2014 Seattle Genetics Inc Earnings Release - After Market Close Feb 10 2015
SEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Feb 06 2015
Seattle Genetics to Present at Leerink Global Healthcare Conference Feb 05 2015
Seattle Genetics to Present at Leerink Global Healthcare Conference Feb 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK